Strategic Advisory Team

BPP has fostered strategic advisory relationships with key visionaries, opinion and thought leaders from across pharma, the biotechnology industry, medical practice, and academic research to ensure that we are driving novel approaches for the rapid advance of innovation in the delivery of safe and cost-effective therapeutics, important diagnostics and new technologies in research, clinical and regulatory practices in the CNS.

Ramon Diaz-Arrastia, MD, PhD
Presidential Professor of Neurology, Penn Medicine
Assoc Director for Clinical Research, Center for Neurodegeneration and Repair, Penn Medicine
Director of Traumatic Brain Injury Clinical Research Center, Penn Medicine
TRACK-TBI Executive Committee
BPP’s Principal Investigator in Clinical Study of neuroinflammation
Micheal Geschwind, MD, PhD
Professor of Neurology, UCSF Memory and Aging Center
Specialist in neurodegenerative disorders, including progressive dementias, prion disease
BPP’s advisor on prion disease models, biomarkers, outcomes
John Kelley
Chairman and Chief Executive Officer, CereScan and CereHealth
Member, Forbes Technology Council
Chairman, President, and Chief Executive Officer of McDATA Corporation
BPP and CereHealth have formed a strategic alliance to advance CereMetrix, an FDA-cleared data analytics platform, to evaluate and correlate outcome measures utilized in CNS clinical trials (including the BPP clinical trial)
Philip Harvey, PhD
Professor of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine. Formerly professor of Psychiatry at Mt. Sinai School of Medicine and
Chief Psychologist at Mt. Sinai Hospital.
Developing composite clinical measure for BPP’s clinical trial in neuroinflammation
Further advising BPP on link between depression and Alzheimer’s Disease